

# Kluwer Patent Blog

## EPO: T 1727/12, European Patent Office, Board of Appeal, Publication Number: 1767375, 1 February 2016

Lars de Haas (V.O.) · Wednesday, June 15th, 2016

The Board of Appeal held that “Biogen insufficiency”, the situation in which the full extent of the monopoly claimed exceeds the technical contribution to the art, is not a distinct ground for invalidity from “classical insufficiency”. Further, the fact that a skilled person is not able to carry out the invention without using the disclosed specific implementation of a generic claim feature is in itself not sufficient to find insufficient disclosure.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

---

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).



Want to improve your IP strategy?

- Manual of Industrial Property
- IP Analytics
- Visser – Annotated European Patent Convention

230+ jurisdictions  
36,000+ cases  
100+ books  
600+ IP law professionals as authors

Request a free demo now  
KluwerIPLaw.com

Wolters Kluwer

This entry was posted on Wednesday, June 15th, 2016 at 10:26 am and is filed under [Case Law](#), [EPO](#), [EPO Decision](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.

